Supramolecular Magnetonanohybrids for Multimodal Targeted Therapy of Triple-Negative Breast Cancer Cells

The authors introduced a novel “all-in-one nanosoldier” made of colloidal hybrid nanostructures, which were designed for simultaneously targeting, imaging, and killing TNBC cells. The results demonstrated that this novel strategy was highly effective for targeting and killing TNBC cells in vitro, expressing high levels of folate membrane-receptors.
[Journal of Materials Chemistry B]
[zotpress userid=’6606345′ items=’M5TS5KL4′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

HDAC6 Plays a Non-canonical Role in the Regulation of Anti-tumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer

Scientists report new non-canonical regulatory properties of ultra-selective histone deacetylase inhibitors over the expression and function of epithelial-mesenchymal transition pathways and the invasiveness potential of breast cancer.
[Cancer Research]
[zotpress userid=’6606345′ items=’H9X2UITC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Deterministic Culturing of Single Cells in 3D

Scientists presented an alternate method to culture individually selected cells in relative isolation from the rest of the population under physiologically relevant matrix conditions. Using examples of breast and colorectal cancers, scientists showed that individual cells evolve into tumors or aspects of tumors displaying different characteristics of the initial cancer type and aggressiveness.
[Scientific Reports]
[zotpress userid=’6606345′ items=’AZ9TJVLH’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Pygopus 2-Histone Interaction Is Critical for Cancer Cell De-Differentiation and Progression in Malignant Breast Cancer

Investigators demonstrated that the histone binding function of Pygo2 was important for driving de-differentiation and malignancy of breast tumors, and loss of this binding activated various differentiation pathways which attenuated primary tumor growth and metastasis formation.
[Cancer Research]
[zotpress userid=’6606345′ items=’8TU7CT2A’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Oncolytics Biotech® Announces Investigator Sponsored Phase II Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

Oncolytics Biotech® Inc announced a new investigator-sponsored triple-negative breast cancer study to be managed by Rutgers Cancer Institute of New Jersey. The phase II trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab in patients with unresectable locally advanced or metastatic TNBC.
[Oncolytics Biotech]
Press Release
Bookmark

No account yet? Register

Share

A Novel Mitochondrial Targeted Hybrid Peptide Modified HPMA Copolymers for Breast Cancer Metastasis Suppression

Researchers designed a mitochondrial targeted drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers to simultaneously inhibit breast cancer progression and metastasis.
[Journal of Controlled Release]
[zotpress userid=’6606345′ items=’GX2U6XSL’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Mechanical Strain Induces Phenotypic Changes in Breast Cancer Cells and Promotes Immunosuppression in the Tumor Microenvironment

Researchers demonstrated that exposure to mechanical strain promoted invasive and pro-tumorigenic phenotypes in breast cancer cells, indicating that mechanical strain could impact the growth and proliferation of cancer cell, alter exosome production by breast cancer, and induce immunosuppression in the tumor microenvironment by dampening anti-tumor immunity.
[Laboratory investigation]
[zotpress userid=’6606345′ items=’6TBDE2XT’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People with Early Triple-Negative Breast Cancer

Genentech announced that the Phase III IMpassion031 study, evaluating Tecentriq® in combination with chemotherapy in comparison to placebo plus chemotherapy, met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer, regardless of PD-L1 expression.
[Genetech]
Press Release
Bookmark

No account yet? Register

Share

YES1 Amplification Confers Trastuzumab–Emtansine (T-DM1) Resistance in HER2-Positive Cancer

The authors revealed that YES1 amplification conferred resistance to HER2-targeted drugs.
[British Journal of Cancer]
[zotpress userid=’6606345′ items=’4UGNEI6H’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

LNC942 Promoting METTL14-Mediated m6A Methylation in Breast Cancer Cell Proliferation and Progression

Investigators unveiled that LINC00942 exerted its functions as an oncogene in promoting METTL14-mediated m6A methylation and regulating the expression and stability of its target genes CXCR4 and CYP1B1 in breast cancer initiation and progression.
[Oncogene]
[zotpress userid=’6606345′ items=’N9C7NILE’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Involvement of Glutathione Peroxidases in the Occurrence and Development of Breast Cancers

The authors focus on the molecular mechanism and function of glutathione peroxidases in the occurrence and development of breast cancer.
[Journal of Translational Medicine]
[zotpress userid=’6606345′ items=’3SXWZDD5′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share